India just one step away from matching China's economy by..., NITI Aayog advisor reveals game-changing strategy; 'If India maintains...'
India just one step away from matching China's economy by..., NITI Aayog advisor reveals game-changing strategy; 'If India maintains...'
India's economy is growing faster than ever, and big changes are on the way. According to Dr. Arvind Virmani, a top advisor at NITI Aayog, India is all set to climb the global economic ladder. In a recent TV interview, he said that India could become the world's third-largest economy by 2027 or 2028, overtaking Germany, which currently holds that spot. He also mentioned that by the end of 2025, India is on track to surpass Japan and become the fourth-largest economy. This prediction matches what the IMF said in its April report. The IMF noted that India's GDP is expected to reach USD 4.19 trillion by 2025, bringing it very close to moving ahead of Japan in global rankings.
'We are the fourth-largest economy as I speak. We are a USD 4 trillion economy, and this is not my data—it's IMF data,' Niti Aayog's chief executive officer BVR Subrahmanyam said during a press briefing on May 24, 2025.
'It is only US, China, Germany, which are larger than India and if we stick to what is being planned and what is being thought through, in 2.5-3 years, we will be the third largest economy,' he added. India could be on the same level as China by 2050
Dr. Arvind Virmani has said that if India's economy keeps growing at a steady rate of 6 to 6.5 per cent every year for the next 25 years, then by 2050, India could be on the same level as China. He also highlighted the importance of the upcoming trade agreement between India and the US, saying it could play a key role in boosting India's economic growth.
Talking about the next few years, he said that clearing up the confusion around tariffs is very important. These uncertainties are currently hurting international trade. In a conversation with news agency PTI, Dr. Virmani added that India is already on its way to becoming the world's fourth-largest economy. He personally believes this could happen by the end of 2025.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Mint
38 minutes ago
- Mint
Need of 6,900 acre land, USD 9 bn investment by 2030 to set up EV infra: Report
New Delhi, Jun 5 (PTI) Nearly 6,900 acre of land and USD 9 billion investments will be required by 2030 for setting up facilities for EV (electric vehicle) manufacturing, lithium-ion battery production and public charging stations, according to Savills India. Real estate consultant Savills India has released report 'Charged for Change: How EVs Are Reshaping Indian Real Estate' stating that the EV market in India has witnessed significant growth in recent years, driven by market forces, government policies, rising environmental concerns, and increasing fuel costs. The government has launched several initiatives to accelerate EV adoption and strengthen the supporting ecosystem. "An investment of USD 7.5 to 9 billion will be required by 2030, primarily for land acquisition and the development of facilities for EV manufacturing, lithium-ion battery production, and public charging stations," the consultant said. In high-adoption scenario, the required investments will be USD 9 billion while USD 7.5 billion will be needed in the case of medium adoption. The report further estimated 5,760 to 6,852 acres of land by 2030 to support EV manufacturing, lithium-ion battery plants, and public charging infrastructure. Srinivas N, Managing Director, Industrial & logistics, Savilla India, said, "Aligning with India's target of achieving 30 per cent EV penetration by 2030, the real estate sector is expected to experience significant growth driven by the rise in EV adoption." The growing demand for EVs will stimulate the need for multiple real estate segments, including industrial and warehousing spaces to support EV and battery manufacturing, EV assembly units, and the storage and distribution of EV components and batteries, he added. Additionally, the expansion of supply chains will increase the demand for strategically located warehouses and logistics parks, said Srinivas. "The government's role with several policies and various initiatives, collectively aims to establish a robust EV ecosystem in the country by fostering innovation, investment and infrastructure development while addressing climate change and energy security concerns," he said. Ministry of Road Transport and Highways (MoRTH), in line with projections by NITI Aayog and the Rocky Mountain Institute (RMI), estimates cumulative EV sales in India to reach 25.3-31.8 million units by 2030 – an annual average of 4.2 to 5.3 million units. According to Savills, this will drive land requirement of 2,009 to 2,467 acres for manufacturing facilities, with a built-up potential of 43.8 to 53.7 million square feet.
Economic Times
an hour ago
- Economic Times
Dr Reddy's, Alvotech join hands to develop biosimilar for cancer treatment
Dr Reddy's (File Photo) Dr Reddy's Laboratories on Thursday said it has joined hands with global biotech firm Alvotech to co-develop and commercialise a biosimilar product for treating multiple types of cancer. The Hyderabad-based drug major has entered into a collaboration and license agreement to co-develop, manufacture and commercialize a biosimilar candidate to Keytruda (pembrolizumab) for global markets, Dr Reddy's Laboratories said in a statement. Keytruda (pembrolizumab) is indicated for the treatment of numerous cancer types. In 2024, worldwide sales of Keytruda were USD 29.5 billion. The collaboration combines Dr Reddy's and Alvotech's proven capabilities in biosimilars thereby speeding up the development process and extending the global reach for this biosimilar candidate, the company noted. Under the terms of the agreement, the parties will be jointly responsible for developing and manufacturing the biosimilar candidate and sharing costs and responsibilities, it stated. Subject to certain exceptions, each party will have the right to commercialize the product globally, it added. "Oncology has been a top focus therapy area for us and this collaboration will further enhance our capabilities in oncology, as pembrolizumab currently represents one of the most critical therapies in immuno-oncology," Dr Reddy's CEO Erez Israeli said. Alvotech chairman and CEO Robert Wessman said the agreement demonstrates Alvotech's ability to leverage its dedicated R&D and manufacturing platform for biosimilars, accelerating the expansion of its pipeline by pursuing growing global markets. "It further enables us to increase the availability of cost-effective, critical biologic medications to patients world-wide," he added. Dr Reddy's shares were trading 3.49 per cent up at Rs 1,295.80 apiece on BSE.
Time of India
an hour ago
- Time of India
Dr Reddy's, Alvotech join hands to develop biosimilar for cancer treatment
Dr Reddy's Laboratories on Thursday said it has joined hands with global biotech firm Alvotech to co-develop and commercialise a biosimilar product for treating multiple types of cancer. The Hyderabad-based drug major has entered into a collaboration and license agreement to co-develop, manufacture and commercialize a biosimilar candidate to Keytruda (pembrolizumab) for global markets, Dr Reddy's Laboratories said in a statement. Keytruda (pembrolizumab) is indicated for the treatment of numerous cancer types. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Con la ayuda de la IA y los CFDs, una inversión puede convertirse en tu ingreso adicional. Trade AI Undo In 2024, worldwide sales of Keytruda were USD 29.5 billion. The collaboration combines Dr Reddy's and Alvotech's proven capabilities in biosimilars thereby speeding up the development process and extending the global reach for this biosimilar candidate, the company noted. Live Events Under the terms of the agreement, the parties will be jointly responsible for developing and manufacturing the biosimilar candidate and sharing costs and responsibilities, it stated. Subject to certain exceptions, each party will have the right to commercialize the product globally, it added. "Oncology has been a top focus therapy area for us and this collaboration will further enhance our capabilities in oncology, as pembrolizumab currently represents one of the most critical therapies in immuno-oncology ," Dr Reddy's CEO Erez Israeli said. Alvotech chairman and CEO Robert Wessman said the agreement demonstrates Alvotech's ability to leverage its dedicated R&D and manufacturing platform for biosimilars, accelerating the expansion of its pipeline by pursuing growing global markets. "It further enables us to increase the availability of cost-effective, critical biologic medications to patients world-wide," he added. Dr Reddy's shares were trading 3.49 per cent up at Rs 1,295.80 apiece on BSE .
